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ABSTRACT
Objective: Patients who frequently receive blood have high risk of hepatitis C virus (HCV) infection. This study aimed to evaluate the prevalence of 
HCV infection and potential risk factors among multiply transfused patients.
Methods: A cross-sectional retrospective study was conducted in the hemophilia unit in Medical City in Baghdad, between June 1, 2016, and 
January 1, 2017. After taking consents and approval of ethical comity, the medical records of 1158 patients with hemophilia A and B, von Willebrand 
disease (vWD), thrombasthenia, Factors VII, X, and XIII deficiencies, and hypofibrinogenemia were analyzed for the presence of HCV antibody using 
(enzyme-linked immunosorbent assay). Cases of hemophilia were classified into mild, moderate, and severe.
Results: The prevalence of HCV infection was 13.2%. Of total, 595 (51.4%) patients had hemophilia A and 99 (16.6%) were anti-HCV positive, while 
225 (19.4%) had hemophilia B and 28 (12.4%) were antibody positive compared to 9 (7%) in vWD. Of those with hemophilia A, 515 (86.6%) had 
severe hemophilia, and 32 (32.32%) cases had acquired HCV infection after 1996 (after introduction of HCV screening in blood banks in Iraq). There 
was a statistically significant association with treatment by Factor VIII only.
Conclusion: The prevalence of HCV in patients with inherited bleeding disorder is 13.2%. In this study, it was found that multitransfusion is the only 
predictor for HCV infection in this group of patients.
Keywords: Hepatitis C virus, Multitransfusion, Prevalence.
INTRODUCTION
Hepatitis C virus (HCV) infection is considered as an important health 
problem, worldwide. It is the most important cause of morbidity and 
mortality in multiply transfused patients due to inherited bleeding 
disorders [1,2]. Most asymptomatic blood donors were found to have 
anti-HCV antibodies and about 20–30% of persons with reported 
cases of acute hepatitis C do recall risk- associated behaviors when 
questioned carefully [3].
Evidence indicated that the risk of acquisition of HCV infection is higher 
in hemophiliacs than patients with other inherited bleeding disorders. 
In most studies, 80–100% of patients remain HCV (RNA) positive, and 
60–80% have persistently elevated liver enzymes [4]. Unfortunately, 
HCV successfully evades the host immune response in 55–85% of 
acutely infected persons, thus leading to chronic infection which can 
lead to cirrhosis and hepatocellular carcinoma [5,6].
Early diagnosis and treatment of HCV infection among patients with 
inherited bleeding disorders is required because the response to 
treatment reduces with age [7].
This study aimed to evaluate the prevalence of HCV infection and 
determine potential risk factors among multiply transfused patients.
METHODS
Study design
This is a cross-sectional retrospective study carried out in the 
hemophilia unit in Children Welfare Teaching Hospital, Medical City in 
Baghdad/Iraq, during a period between June 1, 2016, and January 1, 
2017. This study involved all patients with inherited bleeding disorders 
including hemophilia A and B, von Willebrand disease (vWD), 
thrombasthenia, hypofibrinogenemia, and deficiency of factors (VII, X, 
and XIII); of all ages who were registered in this ward. Demographic 
and virological data from 1158 patients were surveyed and analyzed. 
Testing for HCV antibody using enzyme-linked immunosorbent assay 
(ELISA) test (third generation) was performed in the local hospital 
laboratories at baseline and every 6 months. Hence, those test results 
were extracted from patient records. The level of severity of hemophilia 
A was determined depending on the amount of clotting factor that is 
missing from a person’s blood as shown in Table 1.
Hemophiliacs were classified into mild, moderate, and severe cases 
accordingly [8]. In general, hemophiliacs were treated with FVIII and 
FIX concentrates alone or with factor, blood products, and whole blood. 
Patients after being diagnosed with HCV infection were referred to the 
gastrointestinal center for further management.
Statistical analysis
Minitab 17 program package was used to analyze the data, Anderson-
Darling test was used to test normality of data. Median of data and 
interquartile range (IQR) were used to describe the data. A non-parametric 
method was used to assess the statistical significance between variables, 
Kruskal–Wallis test was used to test the equality of medians for two or more 
variables, while Mann–Whitney U-test was used to test the equality of two 
population medians, and calculate the corresponding p-value. Data were 
presented using bar when presenting prevalence. All data were considered 
significant when *p<0.05 and highly significant when **p<0.001.
RESULTS
Medical records of 1158 patients with inherited bleeding disorders 
were analyzed. Of total, 153 patients were HCV antibody positive with a 
prevalence of 13.2% as shown in Fig. 1.
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As shown in Table 2, 595 (51.4%) were cases with hemophilia A, 
225 (19.4%) with hemophilia B, and 128 (11.1%) with vWD. Of 
153 patients who were infected with HCV, 64.7% were cases of 
hemophilia A and 28 (18.3%) of hemophilia B.
The prevalence of HCV infection was 16.6% in hemophilia A, 12.4% in 
hemophilia B, and 7% in vWD, as shown in Fig. 2.
Since most of the data did not follow normal distribution, non-
parametric methods were used to assess the variation in median of 
data. Median and IQR were selected to present the data. Median age 
(IQR) of patients having hemophilia B, hemophilia A, and vWD was 
31 (10.5), 24 (11.5), 19 (23), respectively. Median age at the diagnosis 
of HCV of the patients with hemophilia A, B, and vWD was almost the 
same (10 years) as shown in Table 3.
Of all patients with hemophilia A with hepatitis, 515 (86.6%) patients 
showed severe Factor VIII deficiency while 80 (13.4%) patients 
had moderate deficiency. Of those with hemophilia B with hepatitis, 
201 (89.3%) showed severe Factor VIII deficiency while 24 (10.71%) 
patients had moderate deficiency without a statistically significant 
difference (p=1).
Factor VIII inhibitors were found in 116 (19.6%) of the cases of 
hemophilia A while none of the cases of hemophilia B showed positive 
to Factor IX with a statistically highly significant difference (p<0.001).
Studying the effect of treatment type (Factor VIII + blood product vs. 
factor only), and age at diagnosis of hemophilia A on infection with HCV, 
showed a relationship between type of treatment and development 
of infection with HCV when holding age at diagnosis constant with a 
statistically significant difference (p=0.03), while age did not display 
such relationship. For patients who were treated with blood product 
and factors, the negative coefficient of −1.43 and the odds ratio (OR) 
of 0.24 indicate that those subjects tend to have a higher HCV infection 
rate than subjects who were treated with factors only. Given that, 
subjects have the same age at diagnosis of hemophilia A, the OR can 
be interpreted as the odds of patients taking blood products having no 
infection with HCV being 24% of the odds of patients taking only factors 
having no HCV infection as shown in Table 4.
As shown in Table 5, treatment type did not affect the number of years 
to get HCV infection from time of the diagnosis of hemophilia A, while 
age at diagnosis of hemophilia showed a statistically significant effect. 
The negative coefficient and an OR <1 indicate that as hemophilia 
A patients diagnosed younger the highest the possibility to get HCV 
infection when holding the effect of treatment type constant.
As shown in Table 6, 32 (32. 32%) cases of hemophilia A who were 
HCV positive had acquired HCV infection after 1996, it means after the 
introduction of screening for HCV in blood donors in Iraq.
Only patients with hemophilia A show a statistically significant 
association between the period of the diagnosis of HCV infection 
whether before or after 1996 and treatment received, the value of 
correlation coefficient (0.375) as shown in Table 7.
DISCUSSION
In the present study, 127 (15.48%) hemophiliacs (type A and B) had 
antibody to HCV. Various studies among multiply transfused hemophilia 
patients demonstrated a wide range of prevalence of the transfusion-
transmitted infections. The prevalence of HCV infection in Iran ranged 
between 29% and 83.3% in different cities or province of Iran. The 
lowest rate was in Zahedan and the highest in Tehran [4,9-11]. The rate 
of HCV infection in one study in Taiwan was 45.7% [12]. It was lower in 
Pakistan (36%) [13].
In the Netherlands, it was found to be 68% [14]. Studies from some 
neighboring Arabic countries reported an HCV infection rate of 78.6% 
among multitransfused patients [15,16]. A study done in Egypt showed 
that HCV prevalence among multitransfused patients ranged between 
10% and 55% [17].
Although patients with thalassemia were not included in this study, it 
is wise to mention that the prevalence of HCV in a study in India was 
18.70% (320 of 1711 patients with thalassemia) [18].
Table 1: Hemophilia A severity
Level Percentage of normal factor VIII activity in blood (%) Number of IUs per milliliter (ml) of whole blood
Normal range 50–150 0.50–1.5 IU
Mild hemophilia 5–40 0.05–0.40 IU
Moderate hemophilia 1–5 0.01–0.05 IU
Severe hemophilia <1 <0.01 IU
IUs: International units
Table 2: The frequency of HCV infection among the study group
Variables All patients number (%) HCV number (%)
Hemophilia A 595 (51.4) 99 (64.7)
Hemophilia B 225 (19.4) 28 (18.3)
vWD 128 (11.1) 9 (5.9)
Thrombasthenia 100 (8.6) 2 (1.3)
Factor VII deficiency 35 (3.0) 5 (3.3)
Factor XIII deficiency 34 (2.9) 2 (1.3)
Hypofibrinogenemia 32 (2.8) 4 (2.6)
Factor X deficiency 9 (0.8) 4 (2.6)
Total 1158 (100) 153 (100)
vWD: Von Willebrand disease, HCV: Hepatitis C virus
Fig. 1: Prevalence of hepatitis C virus infection in inherited 
coagulopathy
Fig. 2: The prevalence of hepatitis C virus infection in the study 
group
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Other studies showed lower rates of HCV infection. Central and 
East Asia and North Africa/Middle East are estimated to have a 
prevalence (>3.5%, 3.5%), whereas Asia Pacific, Tropical Latin America, 
and North America have very low prevalence (<1.5%) [19]. The 
difference observed in different populations may be due to laboratory 
methods and selection methods.
In the present study, the overall prevalence of HCV infection among 
cases of inherited coagulopathy was 13.2% which is considered very 
high because in Iraq hepatitis C is considered of low endemicity 
with a rate of 0.5% in blood donors [20,21] compared with other 
countries. In studies reporting HCV prevalence among hemophiliacs 
in the Maghreb countries, the highest prevalence was reported 
in Libya 94%, while it was 30% in Algeria, and was 42% in 
Morocco [22].
This difference in the prevalence of HCV infection attributed to 
different epidemiological distribution and risk factors of HCV infection 
between these countries. The prevalence of HCV infection in blood 
donors in another study done in Iraq (Baghdad) between 2006 and 
2009 was found to be 0.3% in all donors [23]. This indicates that 
blood product is important predisposing factor to get HCV infection 
despite the extensive screening and disinfection procedure done in 
our country. This could be attributed to the fact that multiple use of 
the same person over time to blood products in their life leads to that 
increased cumulative risk to get HCV infection as shown by Yazdani 
et al. who found that only multitransfusion is independently associated 
with HCV infection [11].
In Iraq, anti-HCV ELISA (third generation) is the only screening 
test for the detection of HCV infection in all blood donors. After 
exposure to HCV, anti-HCV antibodies can be detected by ELISA in 
50–70% of the patients at the onset of symptoms, this percentage 
increased to approximately 90% after 3 months and the remaining 
10% may take even longer, despite the presence of viremia in acute 
infections [24].
The chances of false negativity and false positivity are not uncommon 
like other antigen-antibody-dependent reactions. In early phase of 
acute HCV infection, there is a window period in which the antibodies 
have not yet reached the detectable level by ELISA, and hence, the ELISA 
tests are falsely negative despite the viremia. False positive ELISA tests 
are also not uncommon [25,26]. False positive ELISA for anti-HCV can 
be seen in patients who have cleared the virus after acute infection or 
by therapy and as such may be positive on ELISA which may indicate 
past infection [27].
In high-risk populations, when there is clinical suspicion of HCV 
infection, positive ELISA results confirm the exposure to HCV. 
A qualitative study of HCV RNA should be performed to distinguish 
individuals with chronic infection from those who have eliminated the 
HCV spontaneously [28].
To evaluate which factor leads to this increased prevalence of HCV 
infection in hemophilic patients, we studied hemophilia A patients and 
use logistic regression analysis. We did not find any independent risk 
factor for hepatitis C infection and it seems that multitransfusion is the 
most important risk factor in this regard. Our results were similar to the 
results of Mojtabavi et al., in Isfahan, and some other studies in Iran and 
other countries [29]. While in Jang et al. study, there was a significant 
association of age with anti-HCV seropositivity by logistic regression 
analysis (odds ratio/95% confidence interval [OR/CI]: 1.12/1.07–1.18, 
p<0.001) [12].
In the present study, age at diagnosis of hemophilia showed an effect on 
number of years to get HCV infection in hemophilia A with a statistically 
significant difference (p=0.024). This means that the younger the 
patient the highest the possibility to get HCV infection compared to late 
age at diagnosis when holding the effect of treatment type constant; this 
could be attributed to the fact that as the patient diagnosed younger, he 
gets the highest chance to use more multiple transfusion during his life 
span and more chance to get HCV infection.
The present study showed a statistically significant difference in 
median current age between hemophilia A and B with p=0.0203, but 
the prevalence of HCV infection was not statistically associated with 
Table 3: Distribution of patient’s characteristics
Variables Hemophilia A Hemophilia B vWD■disease p
Current age/year median (IQR) 24 (11.5) 31 (10.5) 19 (23) 0.065
Age/year at Dx. of HCV median (IQR) 10 (6.5) 9 (7.8) 10 (11) 0.098
Severe deficiency (VIII)/number (%) 515 (86.6) 201 (89.3) - 1
Moderate deficiency (VIII)/number (%) 80 (13.4) 24 (10.71) -
VIII inhibitor (%) 116 (19.6) - - <0.001**
IX inhibitor - 0 -
■Von Willebrand disease, **Highly significant difference. vWD: Von Willebrand disease, IQR: Interquartile range, HCV: Hepatitis C virus
Table 4: Binary log regression of treatment type versus age at 
diagnosis of hemophilia A and infection with HCV
Predictor Correlation coefficient p OR**
Treatment* −1.43 0.03 0.24
Age at diagnosis −0.005 0.971 0.99
Treatment*: Factor+blood product versus factors only. OR**: Odds ratio, 
HCV: Hepatitis C virus
Table 5: Ordinal log regression of duration in years from 
diagnosis of hemophilia A to diagnosis of HCV versus treatment 
type and age at diagnosis of hemophilia A
Predictor Correlation coefficient p OR**
Treatment* 0.29 0.433 1.34
Age at diagnosis of 
hemophilia A
−0.26 0.024 0.77
Treatment*: Factor+blood product versus factors only. OR**: Odds ratio, 
HCV: Hepatitis C virus
Table 6: Distribution of the cases of hemophilia A and B and 
patients with vWD according to the period of positivity of 
HCV (before or after 1996)
Variable Count (%)
Hemophilia A
Before 1996 67 (67.68)
After 1996 32 (32.32)
Hemophilia B
Before 1996 24 (85.71)
After 1996 4 (14.29)
vWD*
Before 1996 2 (22.22)
After 1996 7 (77.78)
*Von Willebrand disease. vWD: Von Willebrand disease, HCV: Hepatitis C virus
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the severity of factor VIII deficiency. Similar results were found in a 
study done by Jang et al. [12]. Antibody to HCV was discovered in late 
1987 [9]. In Iraq, viral hepatitis prevention and control program were 
started during early seventies and screening blood donors for HCV 
were introduced in Iraq, in 1996 [10].
The present study showed that 32 (32.32%) cases of hemophilia A 
had acquired HCV infection after 1996, and there was a statistically 
significant association with treatment by Factor VIII only rather than 
combination of factor and whole blood transfusion. Hence, in spite of 
screening method for HCV in blood banks, still there is a risk of getting 
infection during transfusion methods from paramedics or equipment. 
We recommend implementing blood safety strategies, donor selection, 
and quality assured screening of all donated blood and blood 
components as well as strengthening of infection control precautions in 
health-care centers and community settings to prevent viral hepatitis 
infection.
CONCLUSION
In this study, the prevalence of HCV in patients with inherited bleeding 
disorder was 13.2%. It was found that multitransfusion is the only 
predictor for HCV infection in this group of patients. Anti-HCV antibody 
positivity was associated with the age at diagnosis of hemophilia, type 
of treatment, and presence of inhibitory antibodies but not with the 
type of hemophilia nor the severity of the disease.
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